Systemic Immune-Inflammation Index and Mortality in Testicular Cancer: A Systematic Review and Meta-Analysis

• Published in: Diagnostics (Basel) Vol. 13; no. 5; p. 843
• Main Authors: Salazar-Valdivia, Farley E, Valdez-Cornejo, Valeria A, Ulloque-Badaracco, Juan R, Hernandez-Bustamante, Enrique A, Alarcón-Braga, Esteban A, Mosquera-Rojas, Melany D, Garrido-Matta, Diana P, Herrera-Añazco, Percy, Benites-Zapata, Vicente A, Hernandez, Adrian V
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 22.02.2023; MDPI
• Subjects: Bias; Chemotherapy; Cohort analysis; Diagnosis; Health aspects; Immune system; Inflammation; Lymphocytes; Medical prognosis; Meta-analysis; Mortality; Neutrophils; overall survival; Prognosis; progression free survival; Risk factors; Systematic Review; systemic immune-inflammation index; Testicular cancer; Tumors; Peru; Asia; Europe; systemic immune-inflammation index; testicular cancer; meta-analysis; overall survival; progression free survival
• ISSN: 2075-4418; 2075-4418
• DOI: 10.3390/diagnostics13050843

The systemic immune-inflammation index (SIII) is a marker studied in multiple types of urologic cancer. This systematic review evaluates the association between SIII values with overall survival (OS) and progression-free survival (PFS) in testicular cancer. We searched observational studies in five databases. The quantitative synthesis was performed using a random-effects model. The risk of bias was assessed using the Newcastle-Ottawa Scale (NOS). The only measure of the effect was the hazard ratio (HR). A sensitivity analysis was performed according to the risk of bias in the studies. There were 833 participants in a total of 6 cohorts. We found that high SIII values were associated with worse OS (HR = 3.28; 95% CI 1.3-8.9; < 0.001; I = 78) and PFS (HR = 3.9; 95% CI 2.53-6.02; < 0.001; I = 0). No indication of small study effects was found in the association between SIII values and OS ( = 0.5301). High SIII values were associated with worse OS and PFS. However, further primary studies are suggested to enhance the effect of this marker in different outcomes of testicular cancer patients.